Connect Biopharma director lists option holdings

Connect Biopharma Holdings Ltd director James A. Schoeneck reported his initial beneficial ownership of stock options.

Accepted by SEC EDGAR 03/16/2026 - 04:42 PM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Connect Biopharma Holdings Ltd director James A. Schoeneck reported his initial beneficial ownership of stock options. He holds options to purchase 120,000 ordinary shares at an exercise price of $2.38 per share, expiring on July 22, 2035, which vest over three years.

He also holds options to purchase 60,000 ordinary shares at an exercise price of $2.50 per share, expiring on March 2, 2036, which fully vest on March 2, 2027. The filing lists these derivative holdings and does not show any buy or sell transactions.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Schoeneck James A

Role Director

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--

Holdings: Stock Option (Right to Buy) — 180,000 contracts (Direct)

Footnotes (2)

F1. The stock option vests and becomes exercisable over three years, with 1/3 vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next two years.
F2. The stock option fully vests and becomes exercisable on March 2, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CNTB Form 3 filing by James A. Schoeneck show?

The Form 3 shows James A. Schoeneck’s initial reported holdings of stock options in Connect Biopharma, detailing option amounts, exercise prices, expiration dates, and vesting schedules, but no open-market share purchases or sales.

How many Connect Biopharma shares are covered by Schoeneck’s options?

Schoeneck holds stock options covering 180,000 ordinary shares of Connect Biopharma in total, split between 120,000 shares under one option grant and 60,000 shares under a second option grant with separate terms.

What are the exercise prices of Schoeneck’s CNTB stock options?

His options allow purchase of Connect Biopharma ordinary shares at fixed exercise prices of $2.38 and $2.50 per share, defining the cost to acquire shares if he exercises the respective option grants in the future.

When do James A. Schoeneck’s CNTB stock options vest and expire?

One option vests over three years, with one-third after the first anniversary and the rest monthly over two years, expiring on July 22, 2035. The other fully vests on March 2, 2027 and expires on March 2, 2036.

Does the CNTB Form 3 show any stock purchases or sales by Schoeneck?

No, the Form 3 only lists derivative holdings in the form of stock options. It reports the number of underlying ordinary shares, exercise prices, and vesting terms, without recording any purchases, sales, or option exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Schoeneck James A

(Last)

(First)

(Middle)

3580 CARMEL MOUNTAIN ROAD, SUITE 200

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
Connect Biopharma Holdings Ltd [ CNTB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	07/22/2035	Ordinary Shares	120,000	$2.38	D
Stock Option (Right to Buy)	⁽²⁾	03/02/2036	Ordinary Shares	60,000	$2.5	D

Explanation of Responses:

1. The stock option vests and becomes exercisable over three years, with 1/3 vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next two years.

2. The stock option fully vests and becomes exercisable on March 2, 2027.

Remarks:

	/s/ Lisa Peraza attorney-in-fact for James A Schoeneck	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR